Global Work on Microbicide Development

CONRAD provided supplies of the antiretroviral tenofovir (TFV) 1% gel for the CAPRISA 004 Phase IIb clinical trial for HIV prevention in South Africa, which showed TFV 1% gel to be 39% effective in reducing a woman’s risk of becoming infected with HIV during sex. CONRAD also provided TFV 1% gel to other international trials, including the VOICE study by the Microbicide Trials Network, and the FACTS 001 study which CONRAD sponsored.

Preclinical microbicide development, including screening and identification of promising compounds, development of animal models, bioanalytical method development and validation, and product formulation is ongoing by investigators, collaborators and contractors in Germany, Northern Ireland, England, Switzerland, Scotland, Australia, Dominican Republic, South Africa and New Zealand.

Learn more about CONRAD’s global efforts on contraceptive development here.

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 | info@conrad.org